The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Centre For REdefining Antibiotic Use To ReDUce ResistanCE And Prolong The Lives Of Antibiotics (REDUCE)
Funder
National Health and Medical Research Council
Funding Amount
$2,158,296.00
Summary
Ineffective dosing of antimicrobials has contributed to the escalation of antimicrobial resistance which now pervades the healthcare system. Patients in the intensive care unit and post-transplant are examples of patients who commonly have infections, are more likely to fail treatment and have resistant microbes emerge. In these studies we will characterise the doses of antimicrobials that should be used in these difficult-to-treat patients and rapidly share these for routine clinical use.
Ineffective antibiotic therapy is associated with increased mortality in infected patients in the intensive care unit (ICU). Early administration of efficacious antibiotic therapy improves survival substantially. This work seeks to extend upon my previous studies that have described the different concentrations of antibiotics between ICU patients and non-ICU patients. Predicting when to change antibiotic doses in ICU patients is likely to substantially improve patient outcomes.
Innovative Dosing Approaches To Maximise Bacterial Killing And Prevent Resistance In Septic Critically Ill Patients.
Funder
National Health and Medical Research Council
Funding Amount
$830,364.00
Summary
Patients in the intensive care unit (ICU) frequently die from infection. It remains unknown how important antibiotic dose optimisation is for these patients and whether it may enable more effective treatment. In this project, we propose to compare existing approaches to antibiotic dosing in ICU patients with innovative alternatives. We will determine which dosing approach results in better antibacterial efficacy and reduce the development of antibiotic resistance.
Potent Antibiotics Against Drug-resistant Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$531,410.00
Summary
Tuberculosis (TB) is a significant killer and caused 1.7 million deaths in 2009. The disease affects all countries, including Australia, in which the incidence in the indigenous population is 14 times higher than that in the non-indigenous population. We will develop a new anti-TB drug that can replace or enhance the current drugs that are not effective against drug resistant TB.
Development Of New Antibacterial Peptoids To Combat Antibiotic Resistant Bacteria
Funder
National Health and Medical Research Council
Funding Amount
$181,500.00
Summary
The recent emergence of super bug bacterial strains has posed a situation where infections can not be treated. This health problem is growing rapidly with the spread of the resistant bacteria. This proposal intends to develop some of our designed anti-bacterial drugs to the point where they may be incorporated into mass clinical trials. A successful result will yield both a new antibiotic as well as an antibiotic to treat the super bugs.
The Hunt For New-generation Lipopeptide Antibiotics Targeting Gram-negative ‘Superbugs’
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The dry antibiotic discovery and development pipeline, together with the increasing incidence of bacterial resistance in the clinic has been dubbed ‘the perfect storm’. This project involves the design, synthesis and preclinical evaluation of a new generation of polymyxin-like lipopeptides that have low nephrotoxicity and specifically target polymyxin-resistant Gram-negative ‘superbugs’.
Improving The Therapeutic Use Of Anti-infective Agents: Application Of Pharmacometrics For Rational Dosing Regimen Design
Funder
National Health and Medical Research Council
Funding Amount
$313,390.00
Summary
There is no field of medicine in which the individualisation of medicines is more important than in infectious diseases – appropriate doses must be administered to maximise efficacy and to minimise side effects and the emergence of drug-resistance. This fellowship will use the emerging science of pharmacometrics to investigate factors contributing to the variability in response to anti-infective medications and to optimise dosing regimens for the best use of these drugs in clinical practice.
Novel Octapeptin Antibiotics Targeting Extremely Drug Resistant 'superbugs'
Funder
National Health and Medical Research Council
Funding Amount
$946,024.00
Summary
The World Health Organization (WHO) has identified antimicrobial resistance as one of the three greatest threats to human health. Many clinicians worldwide have already been confronted with the reality of infections caused by extremely drug resistant (XDR) bacterial 'superbugs' resistant to all available antibiotics. This project aims to develop safe and efficacious octapeptin antibiotics for the treatment of life-threatening infections caused by problematic XDR ‘superbugs'.
Redefining Antibiotic Dosing To Reduce Bacterial Resistance
Funder
National Health and Medical Research Council
Funding Amount
$474,513.00
Summary
>3000 Australians die every year from severe infections (nearly 3-fold higher in number than our annual road toll). These treatment failures are due to sub-optimal antibiotic dosing from a poor understanding of why concentrations are different in these patients. I will use my laboratory to define what antibiotic concentrations we need to achieve and perform clinical studies with my collaborative network to demonstrate that we can redefine antibiotic dosing to reduce the emergence of superbugs ....>3000 Australians die every year from severe infections (nearly 3-fold higher in number than our annual road toll). These treatment failures are due to sub-optimal antibiotic dosing from a poor understanding of why concentrations are different in these patients. I will use my laboratory to define what antibiotic concentrations we need to achieve and perform clinical studies with my collaborative network to demonstrate that we can redefine antibiotic dosing to reduce the emergence of superbugs.Read moreRead less